ABC News : declared in Colorectal cancer rates increasing sharply among younger adults, study finds

Researchers from the American Cancer Society and the National Cancer Institute looked at colorectal cancer rates from 1974 to 2013 using data from the National Cancer Institute's Surveillance, Epidemiology and End Results Program. Researchers did not specifically study possible reasons why the colorectal cancer rate has increased so dramatically in younger adults. Colorectal cancer rates have been rising sharply in younger adults even as the rate for the population as a whole has dropped, according to a study published today in the Journal of the National Cancer Institute. In addition, understanding how our current diet -- often high in saturates fats, sugars and grains -- can affect cancer risk may be key in understanding the rise in colorectal cancer rates among younger adults, Berlin said. From 1980 to 2013, the incidence of rectal cancer for people in their thirties also increased 3.2 percent per year.

Kite Pharma shares soar after cancer therapy study shows good results

Kite study patients seem to be living longer, but median survival isn't yet known. But after CAR-T therapy last August, he saw his tumors "shrink like ice cubes" and is now in complete remission. That contrasts with Juno Therapeutics Inc., which has had a CAR-T study put on hold twice after five patient deaths due to this problem. It's also being tested for some other types of blood cancer. Patients in the study had one of three types of non-Hodgkin lymphoma, a blood cancer, and had failed all other treatments.


Non-Hodgkin's lymphoma occurs when the body produces too many abnormal lymphocytes, a type of white blood cell. Kite Pharma Inc said on Tuesday its experimental CAR T-cell therapy, which helps the immune system fight cancer, was highly effective in treating aggressive non-Hodgkin's lymphoma, meeting the main goal of a key study. Jefferies analyst Biren Amin said he expected accelerated approval for the drug from the U.S. Food and Drug Administration by the end of 2017. But Juno said in November that five leukemia patients died due to severe brain swelling, raising concerns about its therapy. Kite, citing an interim data from a mid-stage trial, said in September that the experimental therapy was highly effective in treating aggressive non-Hodgkin's lymphoma, although two of the 62 trial patients died.



collected by :Lucy William

To follow all the new news about Disease !!! All you need to know about all kinds of diseases